The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
Open accessAbstract
The recently identified PTEN/MMAC1 gene is a candidate tumor suppressor implicated in multiple tumor types based on mutations or homozygous deletions of the gene in certain human cancers. No studies of PTEN/MMAC1 mRNA or protein expression in cancer cells have been reported, primarily because of significant numbers of normal cells contaminating most tumor samples and because of the lack of antibody reagents. We examined PTEN/MMAC1 in advanced prostate cancer for gene mutations or abnormalities in expression by using a series of recently derived xenografts free of normal human cells and a PTEN/MMAC1-specific antibody. Only 1 of 10 tumors contained a homozygous deletion of PTEN/MMAC1, and no mutations were detected in the entire coding region of the remaining nine xenografts. However, five of these showed reduced or absent PTEN/MMAC1 expression by Northern analysis and reverse transcription–PCR of mRNA. PTEN/MMAC1 mRNA expression was restored in nonexpressing prostate cancer cells by in vitro treatment with the demethylating agent 5-azadeoxycytidine. Alterations in PTEN/MMAC1 expression were confirmed at the protein level by immunoblot analysis, and immunohistochemical studies show that the endogenous wild-type PTEN/MMAC1 protein is localized exclusively in the cytoplasm. These results demonstrate that loss of PTEN/MMAC1 expression occurs frequently in advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., & Linehan, W. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9700 · Cited by 1,529
Herman, J. G., Merlo, A. U., Mao, L., Lapidus, R. G., Issa, J. J., Davidson, N. E., Sidransky, D., & Baylin, S. B. (1995) · PubMed · Cited by 1,341
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M. (1997) · Nature Medicine · doi:10.1038/nm0297-231 · Cited by 1,031
Li, D., & Sun, H. (1997) · PubMed · Cited by 866
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
Myers, M. P., Stolarov, J. P., Eng, C., Li, J., Wang, S. I., Wigler, M. H., Parsons, R., & Tonks, N. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9052 · Cited by 775
Cited by
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Self-citationThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
“In addition, epigenetic downmodulation of PTEN has phosphatase function of the tumor suppressor PTEN is rapidly also been reported (Mutter et al., 2000; Whang et al., 1998).”
BackgroundResultManning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Ten years of protein kinase B signalling: a hard Akt to follow
Brazil, D. P., & Hemmings, B. A. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01958-2 · Cited by 1,177
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Self-citationMolecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
Molecular genetics of prostate cancer
Abate-Shen, C., & Shen, M. M. (2000) · Genes & Development · doi:10.1101/gad.819500 · Cited by 735
NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN
Wang, X., Trotman, L. C., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., Wang, J., Erdjument-Bromage, H., Tempst, P., Cordon-Cardo, C., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.039 · Cited by 720
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15587 · Cited by 674
Self-citationPTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
Tumor Suppressor PTEN Mediates Sensing of Chemoattractant Gradients
Iijima, M., & Devreotes, P. (2002) · Cell · doi:10.1016/s0092-8674(02)00745-6 · Cited by 677
Pten Dose Dictates Cancer Progression in the Prostate
Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Integrin-linked kinase: a cancer therapeutic target unique among its ILK
Hannigan, G., Troussard, A. A., & Dedhar, S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1524 · Cited by 589
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer
Grossmann, M. E., Huang, H., & Tindall, D. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1687 · Cited by 548
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity
Ali, I. U., Schriml, L. M., & Dean, M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1922 · Cited by 542
Madrid, L. V., Wang, C.-Y., Guttridge, D. C., Schottelius, A. J. G., Baldwin, A. S., & Mayo, M. W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1626-1638.2000 · Cited by 540
Clinical, Cellular, and Molecular Aspects of Cancer Invasion
Mareel, M., & Leroy, A. (2003) · Physiological Reviews · doi:10.1152/physrev.00024.2002 · Cited by 524
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
PTEN signaling pathways in melanoma
Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 480
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis
Yamada, K. M., & Araki, M. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2375 · Cited by 479
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
PTEN function: how normal cells control it and tumour cells lose it
LESLIE, N. R., & DOWNES, C. P. (2004) · Biochemical Journal · doi:10.1042/bj20040825 · Cited by 451
Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., Witte, O., Said, J., Loda, M., & Reiter, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203426 · Cited by 436
Self-citationShc and Fak Differentially Regulate Cell Motility and Directionality Modulated by Pten
Gu, J., Tamura, M., Pankov, R., Danen, E. H. J., Takino, T., Matsumoto, K., & Yamada, K. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.2.389 · Cited by 421
PTEN: The down side of PI 3-kinase signalling
Leslie, N. R., & Downes, C. P. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00234-0 · Cited by 415
Wu, X., Hepner, K., Castelino-Prabhu, S., Do, D., Kaye, M. B., Yuan, X.-J., Wood, J., Ross, C., Sawyers, C. L., & Whang, Y. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4233 · Cited by 400
Self-citationPerren, A., Weng, L.-P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 378
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
Self-citationFOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression
Modur, V., Nagarajan, R., Evers, B. M., & Milbrandt, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207509200 · Cited by 371
STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors
Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A. B., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14523 · Cited by 351
Lotan, T. L., Gurel, B., Sutcliffe, S., Esopi, D., Liu, W., Xu, J., Hicks, J. L., Park, B. H., Humphreys, E., Partin, A. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1244 · Cited by 348
Self-citationBaron, V, Adamson, E. D., Calogero, A., Ragona, G., & Mercola, D. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700896 · Cited by 346
PTEN: from pathology to biology
Sulis, M. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00175-2 · Cited by 344
Gimm, O., Perren, A., Weng, L.-P., Marsh, D. J., Yeh, J. J., Ziebold, U., Gil, E., Hinze, R., Delbridge, L., Lees, J. A., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65040-7 · Cited by 327
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., & Ittmann, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201167798 · Cited by 323
Melatonin: An Established Antioxidant Worthy of Use in Clinical Trials
Korkmaz, A., Reiter, R. J., Topal, T., Manchester, L. C., Oter, S., & Tan, D.-X. (2009) · Molecular Medicine · doi:10.2119/molmed.2008.00117 · Cited by 317
Self-citationActivation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion
Shukla, S., MacLennan, G. T., Hartman, D. J., Fu, P., Resnick, M. I., & Gupta, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22862 · Cited by 316
Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., & Reddy, S. A. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207902 · Cited by 303
Goel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2401-2 · Cited by 302
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S. K., Nwokorie, C., Onwudiwe, N., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204736 · Cited by 298
Yoshimoto, M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C. H., Soares, F. A., & Squire, J. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603924 · Cited by 295
Salvesen, H. B., MacDonald, N., Ryan, A., Jacobs, I. J., Lynch, E. D., Akslen, L. A., & Das, S. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010101)91:1<22::aid-ijc1002>3.0.co;2-s · Cited by 294
Planchon, S. M., Waite, K. A., & Eng, C. (2008) · Journal of Cell Science · doi:10.1242/jcs.022459 · Cited by 293
Wang, L., Xiong, H., Wu, F., Zhang, Y., Wang, J., Zhao, L., Guo, X., Chang, L.-J., Zhang, Y., You, M. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.053 · Cited by 288
PTEN, a unique tumor suppressor gene.
Dahia, P. L. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070115 · Cited by 283
Mammalian phosphoinositide kinases and phosphatases
Sasaki, T., Takasuga, S., Sasaki, J., Kofuji, S., Eguchi, S., Yamazaki, M., & Suzuki, A. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.06.001 · Cited by 283
TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
Srivastava, R. K. (2001) · Neoplasia · doi:10.1038/sj.neo.7900203 · Cited by 280
Epigenetic Silencing of the PTEN Gene in Melanoma
Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., & Hengge, U. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0384 · Cited by 279
Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation
Zhou, X.-P., Gimm, O., Hampel, H., Niemann, T., Walker, M. J., & Eng, C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64627-5 · Cited by 278
Dahia, P. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.185 · Cited by 274
Wu, Y., Dowbenko, D., Spencer, S., Laura, R., Lee, J., Gu, Q., & Lasky, L. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909741199 · Cited by 269
Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204257 · Cited by 265
Murillo, H. (2001) · Endocrinology · doi:10.1210/en.142.11.4795 · Cited by 263
(1999) · PubMed · Cited by 258
Kurose, K., Zhou, X.-P., Araki, T., Cannistra, S. A., Maher, E. R., & Eng, C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64681-0 · Cited by 252
PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner
Tang, Y., & Eng, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1557 · Cited by 97
Metadata
- Authors
- Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-04-28
- Volume
- 95
- Issue
- 9
- Pages
- 5246-5250
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2060739426
- Cited by
- 639
- References
- 23
- FWCI
- 41.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.